By vgreene, 7 May, 2020 Lower rate of composite endpoint (ICU transfer, mech vent, death) in post-protocol (35%) vs pre-protocol (54%); median LOS reduced by 3 days w/ CS use
By vgreene, 7 May, 2020 213 hospitalized pts (median 62y; 81 pre-protocol, 132 post-protocol) w/ confirmed mod-severe COVID-19 tx w/ SOC + antivirals; CS dose and duration similar btwn groups but earlier initiation in post group (2 vs 5 days); COPD more frequent in pre-protocol
By vgreene, 7 May, 2020 Multicenter, quasi-experimental study; institutional protocol modified to incl early CS initiation; outcomes compared before and after protocol implementation; post group pts received early methylprednisolone 0.5-1 mg/kg/day IV divided in 2 doses x3 days
By vgreene, 7 May, 2020 Preliminary Evidence From a Multicenter Prospective Observational Study of the Safety and Efficacy of Chloroquine for the Treatment of COVID 19
By vgreene, 7 May, 2020 <a href=https://academic.oup.com/nsr/article/7/9/1428/5848167><b><u>Access <i>Natl Sci Rev</i> article</u></b></a>
By vgreene, 7 May, 2020 Study considerations: non-randomized; historical controls treated w/ various antivirals; demographics and tx differed across time and btwn sites, incl dosing and timing of tx start; mostly moderate dz; incomplete clinical and lab data collection
By vgreene, 7 May, 2020 Primary endpoint of time to viral suppression shorter w/ CQ (difference, 6 days); higher rate of viral clearance w/ CQ vs controls by day 10 (96% vs 91%) and by day 14 (80% vs 57%); duration of fever shorter w/ CQ; no difference in LOS; similar rates of A
By vgreene, 7 May, 2020 Multicenter prospective observational study; 197 hospitalized pts (mean age 44y, 91% moderate dz) w/ confirmed SARS-CoV-2 received CQ (500 mg qd or bid for up to 10 days); 176 historical controls (mean age 46y) received other antiviral tx; time btwn sx on